Erste Asset Management GmbH Acquires 340,700 Shares of Guardant Health, Inc. $GH

Erste Asset Management GmbH lifted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 48.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,045,917 shares of the company’s stock after purchasing an additional 340,700 shares during the period. Guardant Health comprises approximately 0.9% of Erste Asset Management GmbH’s investment portfolio, making the stock its 27th largest holding. Erste Asset Management GmbH’s holdings in Guardant Health were worth $106,781,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Segall Bryant & Hamill LLC raised its stake in shares of Guardant Health by 57.8% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock worth $19,066,000 after purchasing an additional 111,822 shares during the period. TD Asset Management Inc raised its stake in Guardant Health by 16.1% in the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after acquiring an additional 26,210 shares during the period. World Investment Advisors bought a new stake in Guardant Health in the 4th quarter valued at about $1,664,000. GSA Capital Partners LLP raised its stake in Guardant Health by 155.5% in the 3rd quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock valued at $1,373,000 after acquiring an additional 13,378 shares during the period. Finally, Algert Global LLC raised its stake in Guardant Health by 169.1% in the 3rd quarter. Algert Global LLC now owns 120,114 shares of the company’s stock valued at $7,505,000 after acquiring an additional 75,474 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Price Performance

Shares of GH opened at $125.61 on Monday. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $134.28. The stock has a 50 day simple moving average of $99.39 and a two-hundred day simple moving average of $101.12. The firm has a market cap of $16.66 billion, a P/E ratio of -37.05 and a beta of 1.61.

Insider Transactions at Guardant Health

In other Guardant Health news, insider Chris Freeman sold 24,406 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02. Following the completion of the sale, the insider owned 60,034 shares in the company, valued at approximately $7,124,234.78. The trade was a 28.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Meghan V. Joyce sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director owned 11,183 shares of the company’s stock, valued at $1,420,017.34. The trade was a 47.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 350,238 shares of company stock valued at $38,538,372. Insiders own 5.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GH. Citigroup boosted their price objective on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Leerink Partners boosted their price objective on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Raymond James Financial reissued an “outperform” rating and set a $129.00 price objective on shares of Guardant Health in a report on Monday, February 23rd. Canaccord Genuity Group boosted their price objective on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, Evercore raised Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Guardant Health has an average rating of “Buy” and a consensus target price of $137.80.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.